OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases $304,580.16 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 199,072 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was acquired at an average price of $1.53 per share, for a total transaction of $304,580.16. Following the purchase, the chief executive officer now directly owns 211,911,477 shares in the company, valued at approximately $324,224,559.81. The trade was a 0.09 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was acquired at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

OPKO Health stock traded down $0.04 during trading on Friday, hitting $1.54. The stock had a trading volume of 2,936,770 shares, compared to its average volume of 6,884,610. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.75. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The stock’s 50 day moving average is $1.51 and its two-hundred day moving average is $1.45. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -8.32 and a beta of 1.65.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on OPK. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Thursday, September 26th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th.

Institutional Investors Weigh In On OPKO Health

Several institutional investors have recently made changes to their positions in OPK. Rubric Capital Management LP lifted its position in shares of OPKO Health by 800.0% during the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after acquiring an additional 39,486,490 shares in the last quarter. Y.D. More Investments Ltd bought a new position in shares of OPKO Health in the second quarter worth $1,840,000. Assenagon Asset Management S.A. increased its holdings in shares of OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after purchasing an additional 876,272 shares during the period. Clearline Capital LP bought a new position in shares of OPKO Health in the third quarter worth $1,083,000. Finally, Squarepoint Ops LLC bought a new position in shares of OPKO Health in the second quarter worth $592,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.